Study of an experimental TB drug with rifampin for latent TB
Part of Immune system & allergy, Infections clinical trials.
This study tests an investigational drug (MK-8527) combined with a common antibiotic (rifampin) in people with untreated latent TB. It aims to see if the combination is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have latent TB (a silent TB infection) that has not been treated yet.
- You must not have any symptoms of active TB, like a long-lasting cough, fever, night sweats, or weight loss.
- You must not have ever been treated for TB or latent TB.
- You must be generally healthy aside from the latent TB infection.
- You cannot have a weakened immune system, a history of cancer, or certain infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This study looks at whether a rifamycin-containing medicine plan is safe and effective at preventing latent (hidden) TB after a kidney transplant. If your TB test shows you likely have hidden TB, you would be offered treatment to reduce the chance it becomes active TB.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.